Abingdon Health Plc engages in the development, manufacturing, and distribution of diagnostic devices and provide consultancy services to businesses in the diagnostics sector. The company is headquartered in York, North Yorkshire and currently employs 85 full-time employees. The company went IPO on 2020-12-15. The firm is an international developer, manufacturer and distributor of effective rapid tests. Its CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, and others. Its Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests. The Abingdon Simply Test’s other selected self-test products, such as the saliva pregnancy test, Salistick, which is sold through international distributors and through other channels in the United Kingdom and Ireland, such as pharmacy chains.
Follow-Up Questions
Abingdon Health PLC의 CEO는 누구입니까?
Mr. Christopher Yates은 2015부터 회사에 합류한 Abingdon Health PLC의 Chief Executive Officer입니다.
ABDXF 주식의 가격 성능은 어떻습니까?
ABDXF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Abingdon Health PLC의 주요 사업 주제나 업종은 무엇입니까?
Abingdon Health PLC은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Abingdon Health PLC의 시가총액은 얼마입니까?
Abingdon Health PLC의 현재 시가총액은 $0입니다
Abingdon Health PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Abingdon Health PLC에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다